Mavrilimumab (anti-GM-CSF) in GCA, phase 2 GM-CSF upstream to both Th1 & Th17 pathways; potential for dx-modifying?? PNL induction then enrol+PNL taper GCA flare (ESR/CRP+Sx/imaging): mavrilimumab RRR 62% Enormous potential, worth exploring! Cid et al #ACR20 ABSTL06 @RheumNow https://t.co/mq5sTVGbPs